These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

712 related items for PubMed ID: 32155300

  • 21. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH, Tang LQ, Guo SS, Chen QY, Zhang L, Liu LT, Qian CN, Guo X, Xie D, Zeng MS, Mai HQ.
    Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
    [Abstract] [Full Text] [Related]

  • 22. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y, Tang LL, Li YQ, Liu X, Liu Q, Ma J.
    Int J Cancer; 2019 May 01; 144(9):2313-2319. PubMed ID: 30485420
    [Abstract] [Full Text] [Related]

  • 23. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.
    Lin C, Zong J, Lin W, Wang M, Xu Y, Zhou R, Lin S, Guo Q, Chen H, Ye Y, Zhang B, Pan J.
    J Exp Clin Cancer Res; 2018 Nov 26; 37(1):283. PubMed ID: 30477559
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF, Zhang Y, Huang XB, Du XJ, Tang LL, Chen L, Peng H, Guo R, Sun Y, Ma J.
    Chin J Cancer; 2017 Nov 07; 36(1):87. PubMed ID: 29116021
    [Abstract] [Full Text] [Related]

  • 25. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY, Luo DH, Sun XS, Tang LQ, Mai HQ, Chen QY, Zhong JH, Mai DM, Zhang WR, Chen WH, Mo HY.
    Cancer Med; 2019 Nov 07; 8(16):6841-6852. PubMed ID: 31513364
    [Abstract] [Full Text] [Related]

  • 26. Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma.
    Huang CL, Sun ZQ, Guo R, Liu X, Mao YP, Peng H, Tian L, Lin AH, Li L, Shao JY, Sun Y, Ma J, Tang LL.
    Int J Radiat Oncol Biol Phys; 2019 Jun 01; 104(2):355-361. PubMed ID: 30682489
    [Abstract] [Full Text] [Related]

  • 27. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM, Lee VH, Chan SK, Tsang KC, Choi CW, Kwong DL, Lam KO, Chan SY, Tong CC, So TH, Leung TW, Luk MY, Khong PL, Lee AW.
    Br J Cancer; 2019 Oct 01; 121(8):690-698. PubMed ID: 31527689
    [Abstract] [Full Text] [Related]

  • 28. EBV-miR-BART7-3p Imposes Stemness in Nasopharyngeal Carcinoma Cells by Suppressing SMAD7.
    Cai L, Long Y, Chong T, Cai W, Tsang CM, Zhou X, Lin Y, Ding T, Zhou W, Zhao H, Chen Y, Wang J, Lyu X, Cho WC, Li X.
    Front Genet; 2019 Oct 01; 10():939. PubMed ID: 31681406
    [Abstract] [Full Text] [Related]

  • 29. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
    Zhang H, Zou X, Wu L, Zhang S, Wang T, Liu P, Zhu W, Zhu J.
    Cancer Med; 2020 Feb 01; 9(3):1230-1241. PubMed ID: 31856390
    [Abstract] [Full Text] [Related]

  • 30. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
    He SS, Wang Y, Bao Y, Cai XY, Yang XL, Chen DM, Chen Y, Lu LX.
    Cancer Med; 2018 Apr 01; 7(4):1110-1117. PubMed ID: 29493874
    [Abstract] [Full Text] [Related]

  • 31. EBV-miR-BART10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC.
    Yan Q, Zeng Z, Gong Z, Zhang W, Li X, He B, Song Y, Li Q, Zeng Y, Liao Q, Chen P, Shi L, Fan S, Xiang B, Ma J, Zhou M, Li X, Yang J, Xiong W, Li G.
    Oncotarget; 2015 Dec 08; 6(39):41766-82. PubMed ID: 26497204
    [Abstract] [Full Text] [Related]

  • 32. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma.
    Zheng XH, Lu LX, Cui C, Chen MY, Li XZ, Jia WH.
    Oncotarget; 2016 Jan 26; 7(4):4972-80. PubMed ID: 26701721
    [Abstract] [Full Text] [Related]

  • 33. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ, Fang SG, Huang W, Wang HY, Tian YM, Huang RD, Sun Z, Zhao C, Lu TX, Huang Y, Han F.
    Cancer Med; 2019 Aug 26; 8(10):4633-4643. PubMed ID: 31268626
    [Abstract] [Full Text] [Related]

  • 34. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS, Liu LT, Liu SL, Guo SS, Wen YF, Xie HJ, Tang QN, Liang YJ, Li XY, Yan JJ, Ma J, Chen QY, Tang LQ, Mai HQ.
    BMC Cancer; 2019 Jan 21; 19(1):92. PubMed ID: 30665378
    [Abstract] [Full Text] [Related]

  • 35. Epstein-Barr virus-encoded microRNA BART22 serves as novel biomarkers and drives malignant transformation of nasopharyngeal carcinoma.
    Zhang T, Chen Z, Deng J, Xu K, Che D, Lin J, Jiang P, Gu X, Xu B.
    Cell Death Dis; 2022 Jul 30; 13(7):664. PubMed ID: 35907914
    [Abstract] [Full Text] [Related]

  • 36. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR, Du YY, Guo CY, Zhou HX, Lin JY, Meng XH, Mo HY, Luo DH.
    Cancer Res Treat; 2021 Oct 30; 53(4):991-1003. PubMed ID: 33494127
    [Abstract] [Full Text] [Related]

  • 37. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
    Chen WJ, Xu WN, Wang HY, Chen XX, Li XQ, Xie SH, Lin DF, Cao SM.
    BMC Cancer; 2021 Jun 01; 21(1):651. PubMed ID: 34074258
    [Abstract] [Full Text] [Related]

  • 38. Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients--evidence of non-exosomal transport.
    Gourzones C, Ferrand FR, Amiel C, Vérillaud B, Barat A, Guérin M, Gattolliat CH, Gelin A, Klibi J, Chaaben AB, Schneider V, Guemira F, Guigay J, Lang P, Jimenez-Pailhes AS, Busson P.
    Virol J; 2013 Apr 16; 10():119. PubMed ID: 23590857
    [Abstract] [Full Text] [Related]

  • 39. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
    Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, Mo HY, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ.
    Int J Radiat Oncol Biol Phys; 2015 Nov 15; 93(4):862-9. PubMed ID: 26530755
    [Abstract] [Full Text] [Related]

  • 40. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, Liu LZ, Tian L, Luo XT, Xie YB, Ren J, Sun Y, Ma J.
    Cancer; 2019 Jan 01; 125(1):79-89. PubMed ID: 30351466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.